Sg Americas Securities, LLC Ngm Biopharmaceuticals Inc Transaction History

Sg Americas Securities, LLC

$27.6 Billion
Q3 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 06, 2024	SELL	$1.17 - $1.92 $10,122 - $16,611	-8,652 Reduced 36.47%	15,074 $24,000
Q4 2023 Jan 12, 2024	BUY	$0.6 - $1.31 $1,050 - $2,293	1,751 Added 7.97%	23,726 $20,000
Q3 2023 Oct 13, 2023	BUY	$1.05 - $3.37 $23,073 - $74,055	21,975 New	21,975 $24,000
Q1 2023 Apr 28, 2023	BUY	$3.72 - $5.4 $26,359 - $38,264	7,086 Added 49.3%	21,460 $88,000
Q4 2022 Feb 02, 2023	BUY	$3.41 - $12.93 $12,726 - $48,254	3,732 Added 35.07%	14,374 $72,000
Q3 2022 Oct 31, 2022	SELL	$12.59 - $17.67 $13,559 - $19,030	-1,077 Reduced 9.19%	10,642 $139,000
Q2 2022 Jul 29, 2022	SELL	$10.58 - $17.5 $491,345 - $812,717	-46,441 Reduced 79.85%	11,719 $150,000
Q1 2022 Apr 29, 2022	SELL	$13.81 - $18.6 $241,813 - $325,686	-17,510 Reduced 23.14%	58,160 $887,000
Q4 2021 Feb 07, 2022	BUY	$17.26 - $22.02 $892,203 - $1.14 Million	51,692 Added 215.58%	75,670 $1.34 Million
Q3 2021 Nov 01, 2021	SELL	$20.15 - $26.19 $262,252 - $340,862	-13,015 Reduced 35.18%	23,978 $504,000
Q2 2021 Aug 12, 2021	BUY	$15.06 - $30.03 $492,115 - $981,290	32,677 Added 757.11%	36,993 $730,000
Q1 2021 May 13, 2021	SELL	$24.99 - $31.93 $601,234 - $768,203	-24,059 Reduced 84.79%	4,316 $125,000
Q4 2020 Feb 04, 2021	BUY	$16.21 - $31.44 $270,301 - $524,262	16,675 Added 142.52%	28,375 $860,000
Q3 2020 Nov 09, 2020	SELL	$15.59 - $19.97 $1.1 Million - $1.41 Million	-70,648 Reduced 85.79%	11,700 $186,000
Q2 2020 Jul 20, 2020	BUY	$11.97 - $23.47 $859,948 - $1.69 Million	71,842 Added 683.82%	82,348 $1.63 Million
Q1 2020 Apr 30, 2020	BUY	$10.0 - $19.51 $50,300 - $98,135	5,030 Added 91.86%	10,506 $130,000
Q4 2019 Jan 28, 2020	BUY	$9.97 - $20.28 $54,595 - $111,053	5,476 New	5,476 $101,000

Others Institutions Holding NGM

# of Institutions

Shares Held

2.6M

Call Options Held

300

Put Options Held

View Full List

About NGM BIOPHARMACEUTICALS INC

Ticker NGM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 80,365,904
Description
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trial...

More about NGM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Sg Americas Securities, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sg Americas Securities, LLC with notifications on news.

Account